DT56a

derived from soybean, has been shown to relieve menopausal vasomotor symptoms and to increase bone mineral density with no effect on sex steroid hormone levels or endometrial thickness

Also Known As:

Networked: 8 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Yoles, Israel: 3 articles (01/2006 - 11/2003)
2.	Yoles, I: 2 articles (01/2007 - 01/2004)
3.	Katzburg, Sara: 2 articles (01/2006 - 07/2005)
4.	Somjen, Dalia: 2 articles (01/2006 - 07/2005)
5.	Duran, M: 1 article (06/2015)
6.	Hormigo, A: 1 article (06/2015)
7.	Llaneza, P: 1 article (06/2015)
8.	Mendoza, N: 1 article (06/2015)
9.	Navarro, M C: 1 article (06/2015)
10.	Sánchez-Borrego, R: 1 article (06/2015)

Related Diseases

1.	Osteoporosis 01/01/2004 - "In the current study we found that menopausal symptoms were reduced similarly by LD and SD, however for the combined treatment of menopausal symptoms and osteoporosis the standard dosage of 644 mg/day of Femarelle is needed." 07/01/2005 - "DT56a is a natural compound for the treatment of menopausal symptoms and osteoporosis. " 01/01/2006 - "DT56a found to have SERM-like properties is used for the treatment of menopausal symptoms and osteoporosis. " 06/01/2015 - "Although interesting data on relief of vasomotor symptoms have been reported for DT56a, further clinical studies with a greater number of cases and a longer period of study are required to correctly identify its indications for use as an alternative to hormone therapy, especially in preventing osteoporosis. "
2.	Pain (Aches) 09/01/2009 - " purpose of the present study was to evaluate the neuroendocrine effect of DT56a administration through the evaluation of brain content of allopregnanolone (AP), an endogenous neurosteroid gamma-aminobutyric acid agonist with anxiolytic properties, and through the assessment of beta-endorphin (beta-END), the endogenous opioid implicated in pain mechanism, emotional state, and autonomic control. "
3.	Postmenopausal Osteoporosis 01/01/2006 - "In summary, DT56a stimulated sex-specifically female-derived Ob, indicating its unique nature compared to the compounds currently used for postmenopausal osteoporosis by being bone-forming and not only an anti-resorptive agent." 11/01/2003 - "Tofupill appears to be a promising phyto-SERM for the prevention of postmenopausal osteoporosis." 11/01/2003 - "Tofupill/Femarelle (DT56a): a new phyto-selective estrogen receptor modulator-like substance for the treatment of postmenopausal bone loss."
4.	Hepatitis 02/01/2013 - "Oral administration of DT56a also alleviated immune-mediated hepatitis and affected Tregs and NKT cells. " 02/01/2013 - "DT56a was orally administered to mice in three animal models: leptin deficiency, high-fat diet (HFD) supplementation and immune-mediated hepatitis. "
5.	Breast Neoplasms (Breast Cancer) 01/01/2007 - "Pharmacological doses of the natural phyto-SERM DT56a (Femarelle) have no effect on MCF-7 human breast cancer cell-line."

Related Drugs and Biologics

1.	GABA Agonists (GABA Receptor Agonists)
2.	Anti-Anxiety Agents (Anxiolytics)
3.	Pregnanolone (Allopregnanolone)
4.	Hormones (Hormone)
5.	beta-Endorphin (Endorphin, beta)
6.	Opioid Analgesics (Opioids)
7.	Neurosteroids
8.	DT56a
9.	Selective Estrogen Receptor Modulators (SERM)
10.	Leptin

Related Therapies and Procedures

1.	Therapeutics
2.	Oral Administration